SMARCA4 and neoplasm of thorax: In this study, we evaluated the clinicopathological, immunohistochemical, and genetic characteristics of 36 patients with advanced SMARCA4‐deficient thoracic tumors, consisting of 21 SMARCA4‐NSCLCs and 15 SMARAC4‐UTs, and analyzed responses to platinum‐based chemotherapy and PD‐1 inhibitors.